1. Technology Update and Status of Current Clinical Trials
The MitraClip® Therapy
Ferolyn Powell
General Manager
Abbott Vascular Structural Heart
Investigational Device only in the US; Not available for sale in the US

2. The MitraClip® Therapy: A New Treatment Option
Investigational Device only in the US; Not available for sale in the US

3. MitraClip® Therapy Deliver Consistent Results Globally
Physicians at ~ 80 hospitals in Europe and nearly 40 clinical trial sites in the U.S. have treated over 2,600 patients with the MitraClip® system
Iceland
Sweden
Finland
Norway
Russia
Estonia
Latvia
Denmark
Lithuania
Ireland
Russia
Kazakhstan
United
Kingdom
Belarus
Netherlands
Germany
Poland
Belgium
Luxembourg
Ukraine
Czech Rep.
Slovakia
Liechtenstein
Moldova
Austria
France
Switzerland
Hungary
Slovenia
Romania
Italy
Croatia
Georgia
Bosnia
&
Herzegovina
Azerbaijan
Armenia
Marino
San
Serbia
Portugal
Andorra
Montenegro
Bulgaria
Spain
Macedonia
Iran
Albania
Turkey
Greece
Syria
Cyprus
Iraq
Malta
Lebanon
Morocco
Algeria
Tunisia
Israel
Jordan
500 Miles
500 KM
Saudi Arabia
Libya
Egypt
Investigational Device only in the US; Not available for sale in the US

4. MitraClip® Therapy Multi-disciplinary Team Approach
Cardiac Surgeon
Participate in patient selection
Consult during procedure
May Implant the device
Interventional Cardiologist
Echocardiologist
Procedural image guidance (TEE)
Heart Failure Specialist/Clinical Cardiologist/Referring Physician
Participate in patient selection
Manage aftercare
Anesthesiologist
General Anesthesia
Cath Lab Staff
Patient and procedure preparation
Nursing Staff
Aftercare
Investigational Device only in the US; Not available for sale in the US

5. MitraClip® Therapy Start Up Supported by a Robust Training Program
Patient Selection
Etiology, Anatomy, Co-morbidities
Pre-procedure Preparation
Procedural Success
Optimal patient outcome
MitraClip® system functions
Procedural imaging
Procedural Efficiency
Systematic approach
Standardized procedure and images
Clear and consistent terminology
Post-procedure Considerations
Investigational Device only in the US; Not available for sale in the US

6. MitraClip® Therapy Worldwide Experience
>3400 Devices Implanted
* High-surgical Risk estimated based on :
Logistic EuroSCORE ≥ 20; or STS score ≥ 12%; or Surgeon estimate of mortality ≥ 12% Estimate
Estimates of worldwide clinical experience as of January 29th, 2011
Investigational Device only in the US; Not available for sale in the US

7. MitraClip® Therapy Worldwide Prospective Clinical Studies
Core-lab Echo Data: >1,000 total
~ 200 each with 1-year follow-up
~ 100 each with 2-year follow-up
* High-surgical Risk estimated based on :
Logistic EuroSCORE ≥ 20; or STS score ≥ 12%; or Surgeon estimate of mortality ≥ 12%
Estimates of worldwide clinical experience as of January 29th, 2011
Investigational Device only in the US; Not available for sale in the US

8. Safety: 30 Day MAE Intention to Treat
# (%) Patients experiencing event
Device Group
Control Group
(n=95)
All
(n=184)
No Cross-Over ≤ 30 days
(n=170)
Death
2 (1.1%)
2 (2.1%)
Major Stroke
1 RNT
Re-operation of Mitral Valve
1 (1.1%)
Urgent / Emergent CV Surgery
4 (2.2%) 4
4 (4.3%)
Myocardial Infarction
Renal Failure
1 (0.6%) 1
Deep Wound Infection
Ventilation >48 hrs
New Onset Permanent Atrial Fib
Septicemia
GI Complication Requiring Surgery
Transfusions ≥ 2 units of blood
24 (13.3%) 12
42 (44.7%)
TOTAL % of Patients with MAE
15.0%
47.9%
Difference (Device – Control) = -32.9
p<0.0001; (95% CI: -45.0%, -20.7%)
Source: Adapted from Feldman, T. EVEREST II RCT, TCT PML03371 Rev. A.
Investigational Device only in the US; Not available for sale in the US

9. Source: Adapted from Hermiller CRT 2011
Investigational Device only in the US; Not available for sale in the US

10. LV End Systolic Volume, Preliminary 24 Month Results Per Protocol Cohort, Matched Baseline to 12 Months
p=0.0005
p=0.0255
Baseline
(n=118)
12 Months
(n=118)
24 Months
(n=74)
Baseline
(n=65)
12 Months
(n=65)
24 Months
(n=36)
Device
Control
LVESV = left ventricular end systolic volume
p-value compares baseline to 12 month measurements based on matched cases
Source: Adapted from Lim, S., TCT PML03372 Rev. A.
Investigational Device only in the US; Not available for sale in the US

11. NYHA Functional Class, Preliminary 24 Month Results Per Protocol Cohort, Matched Baseline to 12 Months
p<0.0001
p<0.0001 I I I I I I II
84%
NYHA
Class I & II II
100%
NYHA
Class I & II
III
50%
NYHA
Class III
& IV
45%
NYHA
Class III
& IV II II
III II II
III
III IV IV
(n=124)
(n=124)
(n=77)
(n=66)
(n=66)
(n=37)
Device
Control
*p-value compares the distribution of NYHA functional class that occurs in the Device Group vs. the distribution of NYHA functional class that occurs in the Control groups at 12 months (Fishers’ Exact test)
Investigational Device only in the US; Not available for sale in the US
Source: Adapted from Lim, S., TCT PML03372 Rev. A.

12. ACCESS Europe Six Minute Walk Test Baseline and 6 & 12 Months
Baseline & 6 month 6MWT
Matched Data (n = 86)
Baseline & 12 month 6MWT
Matched Data (n = 29)
66 m
p =
61 m
p <
Source: Adapted from Maisano, ACESS Europe, San Raffaele University Hospital
Investigational Device only in the US; Not available for sale in the US 12

13. Abbott Vascular Structural Heart Commitment to the Treatment of Mitral Valve Disease
Investigational Device only in the US; Not available for sale in the US

14. Multi-Disciplinary Team
Abbott Vascular Structural Heart Commitment to the Treatment of Mitral Valve Disease
Global
Multi-Disciplinary Team
Patient Follow-up through 5 years
Clinical Studies
Patients
Investigational Device only in the US; Not available for sale in the US

15. CAUTION: Investigational device limited by Federal (U. S
CAUTION: Investigational device limited by Federal (U.S.) law to investigational use only.
CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, it is important to read the package insert thoroughly for Instructions for Use, Warnings and Potential Complications associated with use of this device. Please check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force. Tests performed by and data on file at Abbott Vascular.
All drawings are artist’s representations only and should not be considered as an engineering drawing or photograph. Photo(s) taken by and on file at Abbott Vascular. MitraClip is a trademark of the Abbott Group of Companies.
© 2011 Abbott Laboratories. All rights reserved. PML3692 Rev. A (02/2011)
Investigational Device only in the US; Not available for sale in the US